Skip to main content
Clinical Trials/IRCT20211012052743N1
IRCT20211012052743N1
Recruiting
Phase 3

Clinical trial study of safety and efficacy assessment of human umbilical cord matrix mesenchymal stem cell infusion on the treatment of new coronavirus 2019 pneumonia in humans

Cell Gene Medicine Company0 sites60 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Cell Gene Medicine Company
Enrollment
60
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Cell Gene Medicine Company

Eligibility Criteria

Inclusion Criteria

  • Patients in the acute phase with Laboratory confirmation of SARS\-COV\-2 infection with RT\-PCR
  • Pneumonia confirmed by chest x\-ray or Computed tomography Scan
  • Respiratory rate\> 30 times/minute
  • Oxygen Saturation less than 93%
  • Arterial oxygen partial pressure (Pao2\) /oxygen inhalation(Fio2\) less than 300 mm Hg
  • No history of tumor or malignant disease
  • CRP greater than normal range

Exclusion Criteria

  • Pregnant patient with a positive pregnancy test or during lactation or who is planning to become pregnant during the study
  • The definitive history of acquired or inherited immune deficiency diseases
  • The definitive psychotic illness, A history of serious mental illness or a history of suicide.
  • Any active or treated Cancerous diseases.
  • Creatinine greater than 1\.7 mg/dL
  • Co\-infection of human immunodeficiency viruses, Hepatitis B, Hepatitis C and Human T\-lymphotropic virus
  • Any cardiac hemodynamic disorder
  • Positive PPD test
  • Positive syphilis test
  • Treatment with cytotoxic drugs one month prior study

Outcomes

Primary Outcomes

Not specified

Similar Trials